Navigation Links
Jules Musing to Lead Business Development Effort
Date:12/7/2011

NEWARK, Del., Dec. 7, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced that Jules A. Musing, an iBio Director, will assume a role as a Managing Director of the Company for at least the next six months in order to accelerate the Company's business development activity.  Mr. Musing, formerly a Senior Executive at Johnson & Johnson, joined iBio's Board of Directors in June of 2011.  In the course of his career in the Pharmaceutical and Biotechnology Industry, Mr. Musing has been President and Managing Director for Johnson & Johnson, Janssen Pharmaceutica, and Ares Serono companies.  At Johnson & Johnson, Mr. Musing was also responsible for worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances.  His activities included the establishment of new scientific and product collaborations in various therapeutic areas, the negotiation of licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide, and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets.

In his role as an iBio Managing Director, Mr. Musing will focus on the Company's business development and licensing activities, including direct dealings with third parties and development of human and material resources to enlarge the Company's business development capacity.

"Jules will help us expand our business development capability rapidly to deal with the product candidates already developed on our platform and those we expect in the next few months," said Robert B. Kay, iBio's Chairman and CEO.  "We expect Jules' experience as a deal maker and his access to senior management in potential users of our technologies to lead to important business opportunities for us in a variety of U.S. and international markets. We are most fortunate to have his participation during this stage of our growth."

About iBio, Inc.iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative of most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.

Forward-Looking StatementsStatements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

 Contacts: 

  

 

 Corporate:

Investor:

  

 

 Robert Erwin, President

Douglas Beck, CFO

 iBio, Inc.

iBio, Inc.

 302-355-2335

302-355-0923

 rerwin@ibioinc.com

ir@ibioinc.com

  


'/>"/>

SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kronos Announces First Quarter Business Update and Financial Results
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. ImaRx Therapeutics Transitions Business Strategy
4. Argonauta Communications Certified as Women-Owned Business by the Womens Business Enterprise National Council (WBENC)
5. New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
6. Small Business Innovation Research Program Awards Grant to Biomoda
7. American Dairy Provides Business Update
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Pharmos Issues Business Update on Dextofisopam Trial and Financing
10. One Call Now Offers Notification Service at NO CHARGE for Governments, Schools, Businesses, Religious Organizations and Others in Response to Swine Flu Outbreak
11. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/29/2016)... -- Automation is one of the best ... growing demands for productivity in speed, accuracy, throughput and ... already adept of a wide range of functions that ... Instrumentation continues to evolve, and is poised to tackle ... years ago. Originally used mostly by the big pharmaceutical ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... Grants Pass, OR (PRWEB) , ... April 29, 2016 , ... ... nutritionists suggest dinner as the meal to miss. That was among the many new ... True Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... media enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, ... as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors ...
Breaking Medicine News(10 mins):